Allworth Financial LP Raises Holdings in IDEXX Laboratories, Inc. (NASDAQ:IDXX)

Allworth Financial LP increased its holdings in IDEXX Laboratories, Inc. (NASDAQ:IDXX) by 61.2% in the fourth quarter, according to the company in its most recent disclosure with the Securities and Exchange Commission (SEC). The firm owned 1,507 shares of the company’s stock after acquiring an additional 572 shares during the quarter. Allworth Financial LP’s holdings in IDEXX Laboratories were worth $649,000 as of its most recent SEC filing.

Other large investors have also modified their holdings of the company. Whittier Trust Co. raised its holdings in IDEXX Laboratories by 10.1% in the third quarter. Whittier Trust Co. now owns 1,673 shares of the company’s stock worth $845,000 after purchasing an additional 153 shares in the last quarter. Eastern Bank acquired a new position in shares of IDEXX Laboratories during the third quarter valued at about $90,000. Lecap Asset Management Ltd. purchased a new position in shares of IDEXX Laboratories in the 3rd quarter valued at approximately $419,000. Commerzbank Aktiengesellschaft FI grew its position in IDEXX Laboratories by 25.7% during the 3rd quarter. Commerzbank Aktiengesellschaft FI now owns 656 shares of the company’s stock worth $332,000 after purchasing an additional 134 shares during the last quarter. Finally, International Assets Investment Management LLC raised its holdings in shares of IDEXX Laboratories by 52,746.0% in the third quarter. International Assets Investment Management LLC now owns 528,460 shares of the company’s stock worth $2,669,890,000 after buying an additional 527,460 shares during the last quarter. Institutional investors own 87.84% of the company’s stock.

Insider Activity

In other news, Director Sophie V. Vandebroek sold 344 shares of the company’s stock in a transaction on Wednesday, November 27th. The stock was sold at an average price of $420.44, for a total value of $144,631.36. Following the transaction, the director now owns 905 shares of the company’s stock, valued at $380,498.20. This represents a 27.54 % decrease in their position. The sale was disclosed in a document filed with the SEC, which is available at this hyperlink. Also, Director M Anne Szostak sold 3,000 shares of the firm’s stock in a transaction dated Friday, February 7th. The stock was sold at an average price of $465.94, for a total value of $1,397,820.00. Following the sale, the director now directly owns 3,061 shares of the company’s stock, valued at $1,426,242.34. The trade was a 49.50 % decrease in their ownership of the stock. The disclosure for this sale can be found here. Insiders sold a total of 13,330 shares of company stock valued at $6,161,276 in the last 90 days. Company insiders own 2.11% of the company’s stock.

Analyst Upgrades and Downgrades

Several brokerages have recently issued reports on IDXX. Leerink Partnrs upgraded IDEXX Laboratories to a “strong-buy” rating in a research note on Monday, December 2nd. Barclays upped their price objective on shares of IDEXX Laboratories from $481.00 to $520.00 and gave the company an “overweight” rating in a report on Tuesday, February 4th. Piper Sandler boosted their target price on shares of IDEXX Laboratories from $435.00 to $510.00 and gave the company a “neutral” rating in a research report on Monday, February 10th. StockNews.com lowered IDEXX Laboratories from a “buy” rating to a “hold” rating in a research note on Wednesday, February 5th. Finally, Bank of America upped their target price on IDEXX Laboratories from $475.00 to $535.00 and gave the stock a “neutral” rating in a research note on Tuesday, February 4th. Four equities research analysts have rated the stock with a hold rating, six have issued a buy rating and one has issued a strong buy rating to the company’s stock. According to MarketBeat.com, the stock has a consensus rating of “Moderate Buy” and an average price target of $533.75.

IDEXX Laboratories Stock Up 0.4 %

NASDAQ IDXX opened at $452.89 on Friday. The business’s fifty day simple moving average is $431.19 and its 200-day simple moving average is $452.42. The company has a quick ratio of 0.95, a current ratio of 1.31 and a debt-to-equity ratio of 0.28. The firm has a market cap of $37.09 billion, a PE ratio of 42.45, a P/E/G ratio of 3.38 and a beta of 1.37. IDEXX Laboratories, Inc. has a 52 week low of $398.50 and a 52 week high of $583.39.

IDEXX Laboratories Company Profile

IDEXX Laboratories, Inc develops, manufactures, and distributes products primarily for the companion animal veterinary, livestock and poultry, dairy, and water testing markets in Africa, the Asia Pacific, Canada, Europe, Latin America, and internationally. The company operates through three segments: Companion Animal Group; Water Quality Products; and Livestock, Poultry and Dairy.